Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Endometrial Neoplasms × ixabepilone × Clear all

Phase

Status

Sponsor Class

OTHER 1 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 19 Neoplasms 8 Neoplasm Metastasis 5 Unspecified Adult Solid Tumor, Protocol Specific 1 Stomach Neoplasms 1 Solid Tumors 1 Solid Malignancies 1 Recurrence 1 Pancreatic Neoplasms 1 Lung Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Advanced Solid Tumors 1

Interventions

pembrolizumab 35 Paclitaxel 30 Carboplatin 26 Doxorubicin 10 Bevacizumab 10 Nivolumab 8 Fulvestrant 8 lenvatinib 7 Docetaxel 7 Cisplatin 7 Pemetrexed 5 Letrozole 5 Ipilimumab 5 Cetuximab 5 spartalizumab 4 dostarlimab 4 Oxaliplatin 4 Irinotecan 4 Gemcitabine 4 Fluorouracil 4 trastuzumab deruxtecan 3 tisotumab vedotin 3 serabelisib 3 selinexor 3 sacituzumab govitecan 3 ribociclib 3 olaparib 3 epacadostat 3 durvalumab 3 cemiplimab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00883116 2017-03-09

IXAMPLE2

R-Pharm

Phase 3 Terminated

551 enrolled 13 charts

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡